Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma

Oncogene

Volumn 32, Issue 36, 2013, Pages 4231-4242

  Barbarulo, A ^a   Iansante, V ^b   Chaidos, A ^c   Naresh, K ^c   Rahemtulla, A ^c   Franzoso, G ^a   Karadimitris, A ^c   Haskard, D O ^d   Papa, S ^b   Bubici, C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF HEPATOLOGY   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

apoptosis; c Jun N terminal kinase; multiple myeloma; PARP14; survival

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 14; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CELL VIABILITY; DISEASE COURSE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MULTIPLE MYELOMA; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN BINDING; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84883743073     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.448     Document Type: Article

References (54)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249-274.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-339.
3. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
4. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3-21.
5. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999; 104: 131-137.
6. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003; 101: 4667-4679.
7. Geest CR, Coffer PJ. MAPK signaling pathways in the regulation of hematopoiesis. J Leukoc Biol 2009; 86: 237-250.
8. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 3100-3112.
9. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol 2010; 149: 537-549.
10. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003; 101: 703-705.
11. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 2006; 70: 1061-1095.
12. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-549.
13. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev 1999; 89: 115-124.
14. Anbalagan M, Sabapathy K. JNK1 and JNK2 play redundant functions in Myc-induced B cell lymphoma formation. Int J Cancer 2012; 130: 1967-1969.
15. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003; 2: 199-201.
16. Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK, Wong AJ. The role of the c-Jun N-terminal kinase 2-a-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene 2011; 30: 234-244.
17. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 1999; 19: 1938-1949.
18. Cui J, Han SY, Wang C, Su W, Harshyne L, Holgado-Madruga M et al. c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res 2006; 66: 10024-10031.
19. Yoon C-H, Kim M-J, Kim R-K, Lim E-J, Choi K-S, An S et al. c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene 2012; 31: 4655-4666.
20. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS et al. c-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003; 9: 391-401.
21. Ke H, Harris R, Coloff JL, Jin JY, Leshin B, Miliani de Marval P et al. The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res 2010; 70: 3080-3088.
22. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 2001; 61: 3908-3912.
23. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008; 118: 3943-3953.
24. Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K. Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 2003; 22: 8797-8801.
25. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-1534.
26. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci 2006; 97: 540-545.
27. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003; 278: 17593-17596.
28. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta 2010; 1804: 463-475.
29. Goenka S, Boothby M. Selective potentiation of Stat-dependent gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor. Proc Natl Acad Sci USA 2006; 103: 4210-4215.
30. Cho SH, Goenka S, Henttinen T, Gudapati P, Reinikainen A, Eischen CM et al. PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood 2009; 113: 2416-2425.
31. Cho SH, Ahn AK, Bhargava P, Lee CH, Eischen CM, McGuinness O et al. Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family. Proc Natl Acad Sci USA 2011; 108: 15972-15977.
32. Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A et al. Regulation of multiple myeloma survival and progression by CD1d. Blood 2009; 113: 2498-2507.
33. Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C et al. Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol 2007; 27: 3920-3935.
34. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003; 77: 8957-8961.
35. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 2005; 106: 1382-1391.
36. Liu J, Minemoto Y, Lin A. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis. Mol Cell Biol 2004; 24: 10844-10856.
37. Ahmed SU, Milner J. Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS One 2009; 4: e7305.
38. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-528.
39. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020-2028.
40. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692-1700.
41. Brune V, Tiacci E, Pfeil I, Dö ring C, Eckerle S, van Noesel CJ et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008; 205: 2251-2268.
42. Gangopadhyay NN, Luketich JD, Opest A, Visus C, Meyer EM, Landreneau R et al. Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines. Cancer Invest 2011; 29: 608-616.
43. Bardwell AJ, Frankson E, Bardwell L. Selectivity of docking sites in MAPK kinases. J Biol Chem 2009; 284: 13165-13173.
44. Cui J, Holgado-Madruga M, Su W, Tsuiki H, Wedegaertner P, Wong AJ. Identification of a specific domain responsible for JNK2alpha2 autophosphorylation. J Biol Chem 2005; 280: 9913-9920.
45. Ke H, Harris R, Coloff JL, Jin JY, Leshin B, Miliani de Marval P et al. The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res 2010; 70: 3080-3088.
46. Ford J, Ahmed S, Allison S, Jiang M, Milner J. JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle 2008; 7: 3091-3097.
47. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006; 2: e40.
48. Goenka S, Cho SH, Boothby M. Collaborator of Stat6 (CoaSt6)-associated poly (ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription. J Biol Chem 2007; 282: 18732-18739.
49. Aravind L. The WWE domain: a common interaction module in protein ubiquitination and ADP ribosylation. Trends Biochem Sci 2001; 26: 273-275.
50. Yanagawa T, Funasaka T, Tsutsumi S, Hu H, Watanabe H, Raz A. Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADPribose) polymerase family-14. Cancer Res 2007; 67: 8682-8689.
51. Zazzeroni F, Papa S, Algeciras-Schimnich A, Alvarez K, Melis T, Bubici C et al. Gadd45beta mediates the protective effects of CD40 costimulation against Fasinduced apoptosis. Blood 2003; 102: 3270-3279.
52. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S et al. Gadd45beta mediates the NF-kappaB suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 2004; 6: 146-153.
53. Blonska M, Pappu BP, Matsumoto R, Li H, Su B, Wang D et al. The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptorsignaling pathway. Immunity 2007; 26: 55-66.
54. Naresh KN, Lampert I, Hasserjian R, Lykidis D, Elderfield K, Horncastle D et al. Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol. J Clin Pathol 2006; 59: 903-911.